首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1727704

癌症領域的精密醫療的共同研究及授權契約:2016年～2025年

Precision Medicine in Oncology Collaboration and Licensing Deals 2016-2025

出版日期: 2025年05月01日 | 出版商:

Current Partnering | 英文 450+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

"腫瘤精準醫療合作與許可交易" 報告提供了前所未有的途徑，讓我們能夠全面了解全球領先生物製藥公司簽署的腫瘤精準醫療交易。

本報告詳細介紹了2016年至2025年期間的腫瘤精準醫療交易，並深入分析了企業達成腫瘤精準醫療交易的方式和原因。這些交易通常包含多個要素，從合作研發到成果商業化。

本報告涵蓋了合作、開發、研究和授權交易。

本報告包含自2016年以來宣布的879項腫瘤精準醫療交易的完整列表，並提供了交易方披露的實際腫瘤精準醫療合作交易的在線交易記錄鏈接。此外，報告還記錄了公司及其合作夥伴向美國證券交易委員會提交的合約文件（如有）。

本報告第一章介紹了精準醫療腫瘤學交易。

第一章是對報告的介紹。

第二章概述了自2016年以來腫瘤精準醫療交易的趨勢。

第三章概述了自2016年以來具有代表性的腫瘤精準醫療交易。交易按交易金額排序。

第四章提供了在腫瘤精準醫療交易領域最活躍的25家公司的綜合列表及其簡要摘要，隨後是腫瘤精準醫療交易的綜合列表以及公開的合同文件。

第五章全面深入地回顧了自2016年1月以來已達成或宣布的腫瘤精準醫療交易，並提供了公開的合約文件。

第六章全面深入地回顧了自2016年1月以來已簽署和宣布的精準醫療腫瘤學合作交易。本章以重點關注的特定腫瘤精準醫療技術類型進行組織。

本章也提供了大量圖表和數據，顯示了自2016年以來精準醫療腫瘤學交易的趨勢和活動。

此外，我們還提供了一個全面的交易目錄，按公司A-Z、交易類型和治療目標進行組織。每個交易標題都透過網頁連結連結到線上交易記錄，並在可用時包含合約文件，方便在需要時輕鬆存取每個合約文件。

主要的優點

精準醫療腫瘤學合作與授權協議為讀者提供以下主要優勢：

了解自2016年以來的交易趨勢
瀏覽精準醫療腫瘤學合作與授權協議。
基準分析 - 確定交易的市場價值
財務條款 - 一次性付款、里程碑付款、特許權使用費
公司 A-Z、交易類型和治療領域分類的交易目錄
主要交易價值
最活躍的交易撮合者
確定每筆交易的資產和交易條款
存取合約文件 - 深入了解交易結構
盡職調查 - 評估擬議交易條款是否適合您的合作夥伴
節省數百小時的研究時間

調查範圍

精準醫療腫瘤學合作與許可協議研究旨在深入了解全球領先生物製藥公司簽署的精準醫療腫瘤學交易的趨勢和交易結構。

精準醫療腫瘤學合作及許可交易包括：

生物製藥產業的精準醫療腫瘤學交易趨勢
製藥和生技產業精準醫療腫瘤學交易記錄目錄
主要的精準醫療腫瘤學交易
最活躍的精準醫療腫瘤學許可交易方
精準醫療腫瘤學合作及許可交易提供全面的交易記錄訪問，包括可用的合約文件。

分析合約有助於進行以下方面的盡職調查：

授予或選擇的具體權利是什麼？
合約實際上授予合作公司什麼？
授予了哪些獨家經營權？
合約的付款結構是怎樣的？
如何審計銷售和付款？
合約期限是多久？
合約的關鍵條款是如何定義的？
知識產權如何處理與歸屬？
誰負責商業化？
誰負責開發、供應和製造？
如何管理保密和資訊揭露？
如何解決爭議？
合約在什麼情況下可以終止？
如果所有權發生變更會怎樣？
雙方同意了哪些分授權和分包條款？
公司堅持哪些樣板條款？
哪些樣板條款似乎因合作夥伴和交易類型而異？
公司主張哪個契約法管轄區？

This report contains a comprehensive listing of 879 precision medicine in oncology deals announced since 2016 including financial terms where available including links to online deal records of actual precision medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of precision medicine in oncology dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in precision medicine in oncology dealmaking since 2016.

Chapter 3 provides an overview of the leading precision medicine in oncology deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in precision medicine in oncology dealmaking with a brief summary followed by a comprehensive listing of precision medicine in oncology deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of precision medicine in oncology deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of precision medicine in oncology partnering deals signed and announced since Jan 2016. The chapter is organized by specific precision medicine in oncology technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in precision medicine in oncology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Precision Medicine in Oncology Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse precision medicine in oncology collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Precision Medicine in Oncology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of precision medicine in oncology trends and structure of deals entered into by leading biopharma companies worldwide.

Precision Medicine in Oncology Collaboration and Licensing Deals includes:

Trends in precision medicine in oncology dealmaking in the biopharma industry
Directory of precision medicine in oncology deal records covering pharmaceutical and biotechnology
The leading precision medicine in oncology deals by value
Most active precision medicine in oncology licensing dealmakers
Precision Medicine in Oncology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in precision medicine in oncology dealmaking

2.1. Introduction
2.2. Precision medicine in oncology deals over the years
2.3. Most active precision medicine in oncology dealmakers
2.4. Precision medicine in oncology deals by deal type
2.5. Precision medicine in oncology deals by therapy area
2.6. Precision medicine in oncology deals by industry sector
2.7. Deal terms for precision medicine in oncology deals
- 2.7.1 Precision medicine in oncology deals headline values
- 2.7.2 Precision medicine in oncology deal upfront payments
- 2.7.3 Precision medicine in oncology deal milestone payments
- 2.7.4 Precision medicine in oncology royalty rates

Chapter 3 - Leading precision medicine in oncology deals

3.1. Introduction
3.2. Top precision medicine in oncology deals by value

Chapter 4 - Most active precision medicine in oncology dealmakers

4.1. Introduction
4.2. Most active precision medicine in oncology dealmakers
4.3. Most active precision medicine in oncology deals company profiles

Chapter 5 - Precision medicine in oncology contracts dealmaking directory

5.1. Introduction
5.2. Precision medicine in oncology contracts dealmaking directory

Chapter 6 - Precision medicine in oncology dealmaking by technology type

Deal directory
Deal directory - Precision medicine in oncology deals by company A-Z
Deal directory - Precision medicine in oncology deals by deal type
Deal directory - Precision medicine in oncology deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Precision medicine in oncology deals since 2016
Figure 2: Active precision medicine in oncology dealmaking activity - 2016 - 2025
Figure 3: Precision medicine in oncology deals by deal type since 2016
Figure 4: Precision medicine in oncology deals by therapy area since 2016
Figure 5: Precision medicine in oncology deals by industry sector since 2016
Figure 6: Precision medicine in oncology deals with a headline value
Figure 7: Precision medicine in oncology deals with an upfront value
Figure 8: Precision medicine in oncology deals with a milestone value
Figure 9: Precision medicine in oncology deals with a royalty rate value
Figure 10: Top precision medicine in oncology deals by value since 2016
Figure 11: Most active precision medicine in oncology dealmakers 2016 - 2025
Figure 12: Precision medicine in oncology deals by technology type since 2016